TriSalus Life Sciences Q2 rev. up 52% YoY to $11.2mln.

• TriSalus Life Sciences Q2 2025 revenue: $11.2M, 52% YoY, 22% QoQ growth • Broadened PEDD portfolio with TriNav FLX launch for tortuous vessels • Revenue guidance confirmed: at least 50% growth due to commercial momentum • Company to host conference call and webcast today at 4:30pm ET

TriSalus Life Sciences Inc. (NASDAQ: TLSI) has announced its second-quarter (Q2) 2025 financial results, showcasing robust growth and a broadened product portfolio. The company reported revenue of $11.2 million, marking a 52% year-over-year (YoY) increase and a 22% quarter-over-quarter (QoQ) growth [2].

The company's President and CEO, Mary Szela, highlighted the strong commercial momentum, stating, "TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical adoption of our TriNav® product suite and proprietary PEDD® platform across a broad range of solid tumor indications" [2].

TriSalus also launched TriNav FLX, an advancement in Pressure Enabled Drug Delivery (PEDD) designed with a more flexible distal tip, enhancing navigability through tortuous vessels. This launch has received a strong early market response, surpassing internal projections [2].

The company reaffirmed its full-year revenue growth guidance of at least 50%, driven by increasing market penetration within liver-directed therapies and new applications. Szela noted, "We are energized by the opportunity to bring our PEDD technology to a wider range of patients which will not only support improved clinical outcomes but also drive deeper physician engagement and commercial momentum, fueling our long-term vision" [2].

TriSalus also reported a net loss of $9.0 million for Q2 2025, compared to $5.1 million for the same period in 2024. The company attributed this increase to non-cash adjustments to the fair value of its contingent earnout liability. Operating losses were $7.3 million, down from $8.2 million in the same period last year, primarily due to reduced research and development expenses associated with the ramp-down of Nelitolimod clinical trial spending [2].

TriSalus will host a conference call and webcast today at 4:30 PM Eastern Time to discuss its financial results. The company has sufficient cash and cash equivalents of $26.5 million to reach positive adjusted EBITDA in the first half of 2026 [2].

References:
[1] https://www.marketbeat.com/instant-alerts/trisalus-life-sciences-tlsi-expected-to-announce-quarterly-earnings-on-tuesday-2025-08-05/
[2] https://www.marketscreener.com/news/trisalus-life-sciences-reports-second-quarter-2025-results-and-reiterates-2025-guidance-ce7c51dadf89f120